Empowered Funds LLC Buys New Stake in Amgen Inc. $AMGN

Empowered Funds LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 95,907 shares of the medical research company’s stock, valued at approximately $34,730,000.

Several other large investors also recently bought and sold shares of AMGN. United Capital Financial Advisors LLC acquired a new position in shares of Amgen during the second quarter valued at approximately $32,897,000. Balanced Rock Investment Advisors LLC purchased a new position in Amgen in the 2nd quarter valued at $225,000. Dearborn Partners LLC acquired a new stake in Amgen during the 2nd quarter worth $699,000. WNY Asset Management LLC purchased a new stake in shares of Amgen during the second quarter worth $211,000. Finally, Bank OZK acquired a new stake in shares of Amgen in the second quarter valued at about $4,270,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Down 0.8%

AMGN opened at $436.99 on Friday. The stock has a market capitalization of $236.25 billion, a PE ratio of 27.16, a P/E/G ratio of 3.18 and a beta of 0.41. Amgen Inc. has a one year low of $269.77 and a one year high of $447.03. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The business’s 50 day moving average price is $386.75 and its 200 day moving average price is $364.23.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the prior year, the company posted $6.02 earnings per share. Amgen’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts expect that Amgen Inc. will post 22.92 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s dividend payout ratio is currently 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire posted strong Phase 3 results in eosinophilic esophagitis (EoE). The drug met both co-primary and all key secondary endpoints, producing statistically significant and clinically meaningful improvements in tissue inflammation and difficulty swallowing. Benefits were sustained through 52 weeks, supporting a potential third approved indication beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 results
• Positive Sentiment: The EoE opportunity could materially expand Tezspire’s commercial potential. Analysts and industry commentators view EoE as a possible blockbuster market, potentially allowing Amgen and partner AstraZeneca to compete more directly with established biologics such as Dupixent. Regulatory filing and approval remain necessary before the opportunity can translate into revenue. Tezspire EoE market opportunity
• Neutral Sentiment: Amgen began a Phase 1 study of AMG 691 aimed at a potentially important Asian market. The trial could add a long-term growth asset, but it is at an early stage and provides limited near-term earnings visibility. AMG 691 Phase 1 trial
• Negative Sentiment: Amgen ended its Crohn’s disease research collaboration with TScan Therapeutics. The decision removes an exclusive effort to identify and develop T-cell targets in inflammatory bowel disease, narrowing one element of Amgen’s early pipeline and highlighting uncertainty around its partnership strategy. Amgen ends Crohn’s disease partnership

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 6,222 shares of company stock valued at $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Argus upped their price objective on shares of Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Morgan Stanley restated an “overweight” rating and issued a $362.00 price target on shares of Amgen in a research report on Wednesday, August 19th. Canaccord Genuity Group lifted their price objective on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Citigroup boosted their price objective on Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Finally, Guggenheim raised their target price on Amgen from $343.00 to $388.00 and gave the stock a “neutral” rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $380.43.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.